148-82-3 | 4-[Bis(2-chloroethyl)amino]-L-phenylalanine

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$68.00	$48.00
50mg	95%	in stock	$105.00	$73.00
100mg	95%	in stock	$184.00	$129.00
250mg	95%	in stock	$332.00	$233.00
500mg	95%	in stock	$510.00	$357.00

Description

• Catalog Number: AB51341
• Chemical Name: 4-[Bis(2-chloroethyl)amino]-L-phenylalanine
• CAS Number: 148-82-3
• Molecular Formula: C13H18Cl2N2O2
• Molecular Weight: 305.2002
• MDL Number: MFCD00057717
• SMILES: ClCCN(c1ccc(cc1)C[C@@H](C(=O)O)N)CCCl
• NSC Number: 757098

Computed Properties

• Complexity: 265
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 19
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 8
• XLogP3: -0.5

Literature

• The PIGRET assay, a method for measuring Pig-a gene mutation in reticulocytes, is reliable as a short-term in vivo genotoxicity test: Summary of the MMS/JEMS-collaborative study across 16 laboratories using 24 chemicals.

  Mutation research 20161115

• Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms.

  Oncotarget 20150922

• Synthesis and analysis of activity of a potential anti-melanoma prodrug with a hydrazine linker.

  European journal of medicinal chemistry 20140101

• FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.

  Chemico-biological interactions 20130905

• Aneugenic potential of the anticancer drugs melphalan and chlorambucil. The involvement of apoptosis and chromosome segregation regulating proteins.

  Journal of applied toxicology : JAT 20130701

• Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.

  Pediatric blood & cancer 20121215

• High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.

  Leukemia & lymphoma 20121201

• Efficient monitoring of in vivo pig-a gene mutation and chromosomal damage: summary of 7 published studies and results from 11 new reference compounds.

  Toxicological sciences : an official journal of the Society of Toxicology 20121201

• Corticosteroid treatment inhibits airway hyperresponsiveness and lung injury in a murine model of chemical-induced airway inflammation.

  Toxicology 20121115

• A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.

  Annals of surgical oncology 20121101

• High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20121101

• Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20121101

• Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.

  Cancer biotherapy & radiopharmaceuticals 20121101

• Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.

  Experimental hematology 20121001

• Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.

  Gastroenterologia y hepatologia 20121001

• Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results.

  The British journal of ophthalmology 20121001

• Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20121001

• Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.

  Leukemia & lymphoma 20120901

• Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120901

• Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.

  American journal of hematology 20120901

• Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.

  Leukemia research 20120901

• How to select among available options for the treatment of multiple myeloma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120901

• Lenalidomide for multiple myeloma.

  The New England journal of medicine 20120809

• Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track.

  The British journal of ophthalmology 20120801

• Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.

  Journal of cellular biochemistry 20120801

• Selective ophthalmic arterial infusion of chemotherapeutic drugs for recurrent retinoblastoma.

  Journal of pediatric hematology/oncology 20120801

• Synthesis and antitumor activity of formononetin nitrogen mustard derivatives.

  European journal of medicinal chemistry 20120801

• Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

  British journal of haematology 20120801

• Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.

  The British journal of ophthalmology 20120801

• Real-time ophthalmoscopic findings of intraophthalmic artery chemotherapy in retinoblastoma.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20120801

• [A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120801

• The mechanism of guanine alkylation by nitrogen mustards: a computational study.

  The Journal of organic chemistry 20120720

• Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma.

  Leukemia & lymphoma 20120701

• Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.

  European journal of haematology 20120701

• Low dose cepharanthine ameliorates immune thrombocytopenic purpura associated with multiple myeloma.

  International immunopharmacology 20120701

• Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients.

  Investigative ophthalmology & visual science 20120628

• Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.

  The Cochrane database of systematic reviews 20120613

• Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer.

  Journal of controlled release : official journal of the Controlled Release Society 20120610

• Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120601

• Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120601

• Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.

  Annals of hematology 20120601

• Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.

  International journal of oncology 20120601

• Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) - a single-center experience.

  Advances in medical sciences 20120601

• Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

  European journal of haematology 20120601

• Evidence that aberrant protein metabolism contributes to chemoresistance in multiple myeloma cells.

  Oncology reports 20120601

• Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.

  British journal of haematology 20120601

• Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

  British journal of haematology 20120601

• Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis.

  American journal of hematology 20120601

• Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.

  Bulletin du cancer 20120601

• Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma.

  Journal of chemotherapy (Florence, Italy) 20120601

• FTIR microspectroscopy discriminates anticancer action on human leukemic cells by extracts of Pinus kesiya; Cratoxylum formosum ssp. pruniflorum and melphalan.

  Talanta 20120515

• Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

  The New England journal of medicine 20120510

• Lenalidomide in myeloma--a high-maintenance friend.

  The New England journal of medicine 20120510

• Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT.

  Bone marrow transplantation 20120501

• A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.

  Cancer 20120501

• Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.

  Leukemia & lymphoma 20120501

• A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities.

  Annals of surgical oncology 20120501

• Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.

  Haematologica 20120501

• Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.

  British journal of haematology 20120501

• Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents.

  Biochemical pharmacology 20120501

• Quality of life outcomes after isolated limb infusion.

  Annals of surgical oncology 20120501

• The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.

  European journal of haematology 20120501

• MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.

  Blood 20120501

• Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.

  European journal of medicinal chemistry 20120501

• Prognostic significance of serum cystatin C in multiple myeloma.

  International journal of hematology 20120501

• Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20120501

• Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120415

• [AL amyloidosis].

  Orvosi hetilap 20120415

• A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.

  Investigational new drugs 20120401

• Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.

  Bone marrow transplantation 20120401

• Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America.

  Bone marrow transplantation 20120401

• Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.

  Leukemia & lymphoma 20120401

• Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma.

  Ophthalmology 20120401

• Successful treatment of systemic capillary leak syndrome with intravenous immunoglobulins.

  Revista clinica espanola 20120401

• Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120401

• Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis.

  Investigative ophthalmology & visual science 20120401

• Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.

  Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20120401

• Multiple myeloma: treatment evolution.

  Hematology (Amsterdam, Netherlands) 20120401

• [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20120401

• Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

  Cancer research 20120315

• FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.

  Hematological oncology 20120301

• A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120301

• Successful cord blood transplantation with reduced-intensity conditioning for childhood cerebral X-linked adrenoleukodystrophy at advanced and early stages.

  Pediatric transplantation 20120301

• Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.

  Leukemia & lymphoma 20120301

• Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.

  Leukemia & lymphoma 20120301

• Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120301

• Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma.

  Ophthalmology 20120301

• Drug interaction between lenalidomide and itraconazole.

  American journal of hematology 20120301

• [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].

  Presse medicale (Paris, France : 1983) 20120301

• [Current perspectives in the treatment of multiple myeloma - news and views].

  Deutsche medizinische Wochenschrift (1946) 20120301

• Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity.

  Clinics (Sao Paulo, Brazil) 20120301

• [Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20120301

• Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.

  Bone marrow transplantation 20120201

• BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin's disease.

  Bone marrow transplantation 20120201

• Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.

  Cancer chemotherapy and pharmacology 20120201

• Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20120201

• [Multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20120201

• Enhancing melanoma treatment with resveratrol.

  The Journal of surgical research 20120101

• Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.

  Bone marrow transplantation 20120101

• Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.

  Annals of hematology 20120101

• Anaplastic atypical myeloma with extensive cutaneous involvement in a dog.

  The Journal of veterinary medical science 20120101

• Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma.

  Ophthalmology 20120101

• Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning.

  European journal of haematology 20120101

• Melphalan in regional chemotherapy for locally recurrent metastatic melanoma.

  Current topics in medicinal chemistry 20120101

• Isolated hypoxic liver perfusion with melfalan in humans and its anesthesiologic aspects.

  Advances in experimental medicine and biology 20120101

• Melphalan plus prednisolone in the treatment of multiple myeloma.

  Mymensingh medical journal : MMJ 20120101

• Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.

  Mymensingh medical journal : MMJ 20120101

• Bone marrow osteoblast damage by chemotherapeutic agents.

  PloS one 20120101

• [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].

  Vnitrni lekarstvi 20120101

• Oxidative protein damage with carbonyl levels and nitrotyrosine expression after chemotherapy in bone marrow transplantation patients.

  Pharmacology 20120101

• Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review.

  PloS one 20120101

• Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.

  Internal medicine (Tokyo, Japan) 20120101

• Myeloma and second primary cancers.

  The New England journal of medicine 20111208

• Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.

  Bone marrow transplantation 20111201

• The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.

  European journal of oncology nursing : the official journal of European Oncology Nursing Society 20111201

• Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.

  Annals of hematology 20111201

• Identification of biomarkers of chemically induced hepatocarcinogenesis in rasH2 mice by toxicogenomic analysis.

  Archives of toxicology 20111201

• The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.

  Leukemia 20111201

• Intracellular ATP levels determine cell death fate of cancer cells exposed to both standard and redox chemotherapeutic agents.

  Biochemical pharmacology 20111201

• Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.

  Haematologica 20111201

• Technique and outcomes of isolated limb infusion for locally advanced malignant melanoma--a radiological perspective.

  Clinical radiology 20111201

• Anti-tumoral activities of dioncoquinones B and C and related naphthoquinones gained from total synthesis or isolation from plants.

  European journal of medicinal chemistry 20111201

• The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Is the low-thalidomide dose MPT regimen beneficial?

  The Korean journal of internal medicine 20111201

• A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.

  The Korean journal of internal medicine 20111201

• Timing of the high-dose therapy in the area of new drugs.

  Srpski arhiv za celokupno lekarstvo 20111201

• [New concept of the treatment in elderly patients with multiple myeloma].

  Srpski arhiv za celokupno lekarstvo 20111201

• Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.

  Blood 20111124

• Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.

  International journal of radiation oncology, biology, physics 20111101

• Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.

  Annals of hematology 20111101

• [Current treatment of AL amyloidosis].

  Nephrologie & therapeutique 20111101

• [New insights in the treatment of myeloma with renal failure].

  Nephrologie & therapeutique 20111101

• Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20111101

• Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20111101

• Histopathologic observations after intra-arterial chemotherapy for retinoblastoma.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20111101

• Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX.

  Clinical immunology (Orlando, Fla.) 20111101

• [Pneumonia and Rothia dentocariosa].

  Medecine et maladies infectieuses 20111101

• Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.

  Journal of pediatric surgery 20111101

• Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20111101

• Intra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial?

  Archives of ophthalmology (Chicago, Ill. : 1960) 20111101

• Superselective intraophthalmic artery chemotherapy: what we do not know.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20111101

• AL amyloidosis in a patient with macroglossia.

  ANZ journal of surgery 20111101

• High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma.

  Bone marrow transplantation 20111001

• High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20111001

• Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?

  Journal of clinical pathology 20111001

• A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.

  Leukemia & lymphoma 20111001

• Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20111001

• Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis.

  Ophthalmology 20111001

• Heavy-chain amyloidosis in TGFBI-negative and gelsolin-negative atypical lattice corneal dystrophy.

  Cornea 20111001

• A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.

  British journal of haematology 20111001

• A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.

  Transplantation proceedings 20111001

• Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.

  Transplantation proceedings 20111001

• BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

  Blood 20110922

• Different sensitivity of BALB/c 3T3 cell clones in the response to carcinogens.

  Toxicology in vitro : an international journal published in association with BIBRA 20110901

• Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators.

  European journal of medicinal chemistry 20110901

• Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.

  Blood 20110901

• Highlighting complications over successes in occurrence of sectoral choroidal occlusive vasculopathy.

  Retina (Philadelphia, Pa.) 20110901

• [Pulmonary Langerhans histiocytosis and Hodgkin's lymphoma].

  Revue des maladies respiratoires 20110901

• Cardiac amyloidosis: a treatable disease, often overlooked.

  Circulation 20110830

• Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

  Blood 20110804

• Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110801

• Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis.

  Clinical and experimental nephrology 20110801

• Characterization of environmental chemicals with potential for DNA damage using isogenic DNA repair-deficient chicken DT40 cell lines.

  Environmental and molecular mutagenesis 20110801

• Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.

  Leukemia & lymphoma 20110801

• [Significance of intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation for treatment of acute leukemias].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801

• Isolated limb perfusion for unresectable extremity sarcoma: results of 2 single-institution phase 2 trials.

  Cancer 20110715

• A Phase I trial: dose escalation of melphalan in the 'BEAM' regimen using amifostine cytoprotection.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110701

• Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.

  Annals of hematology 20110701

• Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110701

• Effect of cobalt-60 (γ radiation) on multidrug-resistant multiple myeloma cell lines.

  Cell biology international 20110701

• ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy.

  Pediatric blood & cancer 20110701

• Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110701

• Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution.

  Annals of surgical oncology 20110701

• Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701

• Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.

  American journal of hematology 20110701

• Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms.

  Archives of surgery (Chicago, Ill. : 1960) 20110701

• [Autophagy: a necessary allied in the growth of pancreatic adenocarcinoma].

  Bulletin du cancer 20110701

• Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.

  Blood 20110609

• Complete regression of retinoblastoma following intra-arterial chemotherapy.

  Journal of pediatric ophthalmology and strabismus 20110607

• The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.

  Bone marrow transplantation 20110601

• Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110601

• Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors.

  Journal of neurosurgery 20110601

• Treatment of newly diagnosed myeloma in patients not eligible for transplantation.

  Current hematologic malignancy reports 20110601

• Melphalan-induced supraventricular tachycardia: incidence and risk factors.

  Clinical cardiology 20110601

• Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.

  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20110601

• In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines.

  The Journal of surgical research 20110515

• Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• 3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.

  Journal of medicinal chemistry 20110512

• Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.

  Bone marrow transplantation 20110501

• Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

  Bone marrow transplantation 20110501

• Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.

  Transfusion 20110501

• Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110501

• Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives.

  Bioorganic & medicinal chemistry letters 20110501

• Myelodysplasia in the Wellington region 2002-2007: disease incidence and treatment patterns.

  Internal medicine journal 20110501

• Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

  European journal of haematology 20110501

• Bivalent bendamustine and melphalan derivatives as anticancer agents.

  European journal of medicinal chemistry 20110501

• [Autologous stem cell transplantation in the treatment of multiple myeloma--single center experience].

  Vojnosanitetski pregled 20110501

• Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.

  Bone marrow transplantation 20110401

• Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110401

• Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.

  Brain tumor pathology 20110401

• Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.

  Leukemia 20110401

• Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.

  Japanese journal of clinical oncology 20110401

• Recent advances in myeloma treatment.

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20110401

• Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.

  British journal of haematology 20110401

• (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.

  Clinical lymphoma, myeloma & leukemia 20110401

• Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110320

• Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates.

  Bioorganic & medicinal chemistry 20110315

• Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110301

• Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.

  Annals of hematology 20110301

• The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients.

  Leukemia research 20110301

• Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.

  European journal of cancer (Oxford, England : 1990) 20110301

• Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

  European journal of haematology 20110301

• Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma.

  Retina (Philadelphia, Pa.) 20110301

• High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.

  Pediatric hematology and oncology 20110301

• Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.

  Cancer investigation 20110301

• De novo AL amyloidosis in the kidney allograft.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20110301

• [A case of aggressive multiple myeloma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• Inhalation of alkylating mustard causes long-term T cell-dependent inflammation in airways and growth of connective tissue.

  Toxicology 20110227

• BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.

  Leukemia research 20110201

• Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications.

  Cancer 20110201

• National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

  Pediatric blood & cancer 20110201

• Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?

  Annals of surgical oncology 20110201

• Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

  Blood 20110113

• Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.

  Blood 20110106

• Factors associated with recovery of renal function in patients with multiple myeloma who were treated with hemodialysis.

  Nephron. Clinical practice 20110101

• A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C).

  Biochemical pharmacology 20110101

• Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

  European journal of haematology 20110101

• Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient: case report.

  Anti-cancer drugs 20110101

• Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.

  European journal of haematology 20110101

• CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma.

  Pediatric blood & cancer 20110101

• Regional treatment strategies for in-transit melanoma metastasis.

  Surgical oncology clinics of North America 20110101

• Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.

  American journal of hematology 20110101

• Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities.

  European journal of medicinal chemistry 20110101

• [New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome].

  Revue neurologique 20110101

• [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101

• History of multiple myeloma.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines.

  PloS one 20110101

• [High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience].

  Przeglad lekarski 20110101

• Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen.

  Medical science monitor : international medical journal of experimental and clinical research 20110101

• Relapsed multiple myeloma presenting as an orbital plasmacytoma.

  Ophthalmic plastic and reconstructive surgery 20110101

• Light chain (AL) amyloidosis: update on diagnosis and management.

  Journal of hematology & oncology 20110101

• Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.

  Blood 20101202

• Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

  Blood 20101202

• CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.

  Bone marrow transplantation 20101201

• Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease.

  International journal of clinical oncology 20101201

• Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101201

• Use of an automated circuit for isolated limb infusion for malignancy.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20101201

• Structure-cytotoxicity relationship in a series of N-phosphorus substituted E,E-3,5-bis(3-pyridinylmethylene)- and E,E-3,5-bis(4-pyridinylmethylene)piperid-4-ones.

  European journal of medicinal chemistry 20101201

• Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.

  Bioorganic & medicinal chemistry letters 20101201

• Elevated fructosamine concentrations caused by IgA paraproteinemia in two dogs.

  Journal of veterinary science 20101201

• Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20101201

• Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.

  Molecular cancer therapeutics 20101201

• The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.

  British journal of clinical pharmacology 20101201

• Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101120

• Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.

  Blood 20101111

• Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.

  Leukemia research 20101101

• Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

  Haematologica 20101101

• Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

  The Lancet. Oncology 20101101

• Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-β-cyclodextrin or a co-solvent system.

  Biopharmaceutics & drug disposition 20101101

• Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.

  Transplantation proceedings 20101101

• Double high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor.

  Future oncology (London, England) 20101101

• [New treatment strategy for Crow-Fukase (POEMS) syndrome].

  Rinsho shinkeigaku = Clinical neurology 20101101

• Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.

  Transplantation 20101027

• Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

  Blood 20101021

• Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020

• Optimization of the N-lost drugs melphalan and bendamustine: synthesis and cytotoxicity of a new set of dendrimer-drug conjugates as tumor therapeutic agents.

  Bioconjugate chemistry 20101020

• A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101015

• Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.

  International journal of radiation oncology, biology, physics 20101001

• Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20101001

• A case of aggressive myeloma recognized shortly after the remission following high-dose chemotherapy with autologous peripheral blood stem cell transplantation.

  International journal of hematology 20101001

• High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.

  American journal of hematology 20101001

• Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

  The Lancet. Oncology 20101001

• Optimising bortezomib in newly diagnosed multiple myeloma.

  The Lancet. Oncology 20101001

• Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.

  American journal of hematology 20101001

• Multiple myeloma in the elderly: when to treat, when to go to transplant.

  Oncology (Williston Park, N.Y.) 20101001

• Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.

  Blood 20100902

• Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.

  European journal of haematology 20100901

• Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity.

  Expert opinion on drug metabolism & toxicology 20100901

• Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.

  American journal of hematology 20100901

• Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100801

• Immunomagnetic selection of CD34(+) cells carried out in cryopreserved cell concentrates from a paediatric patient affected with non-Hodgkin lymphoma.

  Transfusion medicine (Oxford, England) 20100801

• Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.

  Annals of hematology 20100801

• Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery).

  Ophthalmology 20100801

• Renal involvement of monoclonal immunoglobulin deposition disease associated with an unusual monoclonal immunoglobulin A glycan profile.

  Clinical and experimental nephrology 20100801

• Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.

  Leukemia & lymphoma 20100801

• Successful treatment of late, recurrent wilms tumor with high-dose chemotherapy and autologous stem cell rescue in third complete response.

  Journal of pediatric hematology/oncology 20100801

• Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.

  Clinical lymphoma, myeloma & leukemia 20100801

• First-line treatment of elderly multiple myeloma patients.

  Clinical advances in hematology & oncology : H&O 20100801

• Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.

  Blood 20100729

• The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.

  Blood 20100722

• XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.

  Blood 20100715

• Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.

  Bone marrow transplantation 20100701

• Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.

  Haematologica 20100701

• Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.

  Leukemia research 20100701

• Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.

  Cancer immunology, immunotherapy : CII 20100701

• Renal impairment due to white-cell lysis after G-CSF and chemotherapy during pediatric autologous stem cell transplantation.

  Journal of pediatric hematology/oncology 20100701

• A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay.

  International journal of oncology 20100701

• Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701

• Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

  Molecular cancer therapeutics 20100701

• Systemic chemotherapy-induced microsatellite instability in the mononuclear cell fraction of women with breast cancer can be reproduced in vitro and abrogated by amifostine.

  The Journal of pharmacy and pharmacology 20100701

• HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.

  Blood 20100624

• Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier.

  Bioorganic & medicinal chemistry letters 20100615

• BALB/c 3T3 cell transformation assay for the prediction of carcinogenic potential of chemicals and environmental mixtures.

  Toxicology in vitro : an international journal published in association with BIBRA 20100601

• ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.

  European journal of haematology 20100601

• High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20100601

• Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports.

  International journal of hematology 20100601

• Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.

  Clinical lymphoma, myeloma & leukemia 20100601

• A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.

  American journal of hematology 20100601

• Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure.

  American journal of hematology 20100601

• Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100510

• Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma.

  Annals of hematology 20100501

• Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).

  Annals of hematology 20100501

• The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.

  Biochemical pharmacology 20100501

• Long term survival of primary skeletal muscle lymphoma in a miniature dachshund.

  The Journal of veterinary medical science 20100501

• A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide.

  Leukemia 20100501

• Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100501

• Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.

  Leukemia 20100501

• Symmetrical alpha-bromoacryloylamido diaryldienone derivatives as a novel series of antiproliferative agents. Design, synthesis and biological evaluation.

  Bioorganic & medicinal chemistry letters 20100501

• High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study.

  Pediatric hematology and oncology 20100501

• Frontline regimens for multiple myeloma patients.

  Clinical advances in hematology & oncology : H&O 20100501

• Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

  British journal of clinical pharmacology 20100501

• Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma.

  Bone marrow transplantation 20100401

• A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors.

  Journal of neuro-oncology 20100401

• BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study.

  Bone marrow transplantation 20100401

• Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.

  European journal of haematology 20100401

• Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.

  British journal of haematology 20100401

• Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.

  Leukemia & lymphoma 20100401

• Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma.

  Retina (Philadelphia, Pa.) 20100401

• Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.

  Molecular cancer therapeutics 20100401

• [Crow-Fukase (POEMS) syndrome].

  Brain and nerve = Shinkei kenkyu no shinpo 20100401

• Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).

  Hematology (Amsterdam, Netherlands) 20100401

• [Rib fracture with severe cause].

  MMW Fortschritte der Medizin 20100401

• [Multiple myeloma complicated with Takotsubo cardiomyopathy].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100401

• POEMS syndrome: a rare case of monoclonal plasmaproliferative disorder.

  Acta medica Indonesiana 20100401

• IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.

  Blood 20100325

• Potent DNA-directed alkylating agents: Synthesis and biological activity of phenyl N-mustard-quinoline conjugates having a urea or hydrazinecarboxamide linker.

  Bioorganic & medicinal chemistry 20100315

• Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.

  Bone marrow transplantation 20100301

• DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.

  European journal of haematology 20100301

• The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.

  European journal of haematology 20100301

• Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.

  European journal of haematology 20100301

• Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.

  European journal of haematology 20100301

• Synthesis, characterization and structure-activity relationship of novel N-phosphorylated E,E-3,5-bis(thienylidene)piperid-4-ones.

  European journal of medicinal chemistry 20100301

• Glutathione S-transferase M1 inhibits dexamethasone-induced apoptosis in association with the suppression of Bim through dual mechanisms in a lymphoblastic leukemia cell line.

  Cancer science 20100301

• Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.

  Bioorganic & medicinal chemistry letters 20100301

• Novel melphalan and chlorambucil derivatives of 2,2,6,6-tetramethyl-1-piperidinyloxy radicals: synthesis, characterization, and biological evaluation in vitro.

  Chemical & pharmaceutical bulletin 20100301

• Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20100301

• A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

  Blood 20100211

• Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100210

• A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

  Blood 20100204

• Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.

  Bone marrow transplantation 20100201

• The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.

  British journal of haematology 20100201

• Ethanol induction of steroidogenesis in rat adrenal and brain is dependent upon pituitary ACTH release and de novo adrenal StAR synthesis.

  Journal of neurochemistry 20100201

• Thalidomide-induced phrenic nerve paralysis.

  Leukemia & lymphoma 20100201

• 3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy.

  Bioorganic & medicinal chemistry letters 20100201

• Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.

  American journal of hematology 20100201

• Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20100201

• The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance.

  Molecular cancer therapeutics 20100201

• Whither the bone marrow transplant?

  Hematology (Amsterdam, Netherlands) 20100201

• Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.

  Hematology (Amsterdam, Netherlands) 20100201

• Uptake of 3-[125I]iodo-alpha-methyl-L-tyrosine into colon cancer DLD-1 cells: characterization and inhibitory effect of natural amino acids and amino acid-like drugs.

  Nuclear medicine and biology 20100201

• Real-time monitoring of drug release.

  Chemical communications (Cambridge, England) 20100128

• Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

  Blood 20100107

• 'Short course' bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100101

• Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.

  British journal of haematology 20100101

• Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.

  Neurosurgery 20100101

• IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.

  Pathology 20100101

• New treatments for myeloma.

  Joint, bone, spine : revue du rhumatisme 20100101

• Rhegmatogenous retinal detachment following treatment for retinoblastoma.

  Journal of pediatric ophthalmology and strabismus 20100101

• INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

  Neoplasia (New York, N.Y.) 20100101

• New developments in the treatment of patients with multiple myeloma.

  The Netherlands journal of medicine 20100101

• Impedance cardiography in the diagnosis of capillary leak syndrome caused by doxorubicin therapy in a patient with myeloma multiplex.

  Cardiology journal 20100101

• [Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100101

• Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.

  PloS one 20100101

• A case of γ1-heavy chain deposition disease successfully treated with melphalan and prednisolone therapy.

  Internal medicine (Tokyo, Japan) 20100101

• Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.

  Oncology 20100101

• [Autologous peripheral blood hematopoietic cell transplantation in the treatment of AL-amyloidosis].

  Terapevticheskii arkhiv 20100101

• VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091220

• Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.

  Cancer research 20091215

• Researchers debate best use of stem cell transplants in patients with multiple myeloma.

  Journal of the National Cancer Institute 20091202

• Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.

  European journal of haematology 20091201

• Successful bortezomib-based treatment in POEMS syndrome.

  European journal of haematology 20091201

• Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

  Targeted oncology 20091201

• Synthesis, anticancer and cytostatic activity of some 6H-indolo[2,3-b]quinoxalines.

  Acta pharmaceutica (Zagreb, Croatia) 20091201

• Common peroneal nerve palsy following TNF-based isolated limb perfusion for irresectable extremity desmoid tumor.

  Orthopaedics & traumatology, surgery & research : OTSR 20091201

• Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.

  Transplantation proceedings 20091201

• Treatment of multiple myeloma: 2009 update.

  Prescrire international 20091201

• Thalidomide maintenance in multiple myeloma: certainties and controversies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110

• Cutaneous involvement in multiple myeloma and bortezomib.

  Annals of hematology 20091101

• Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.

  Bone marrow transplantation 20091101

• Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20091101

• A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091101

• Triple MEL100 therapy in multiple myeloma.

  Transplantation proceedings 20091101

• Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20091101

• [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].

  Vnitrni lekarstvi 20091101

• Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma.

  Anticancer research 20091101

• Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.

  Cancer 20091015

• Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20091001

• Estrogen increases survival in an orthotopic model of glioblastoma.

  Journal of neuro-oncology 20091001

• Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

  Leukemia 20091001

• First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective.

  Current drug targets 20091001

• Assays for the quantification of melphalan and its hydrolysis products in human plasma by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• Treatment of multiple myeloma in patients with Gaucher disease.

  American journal of hematology 20091001

• [Hematopoietic stem cell transplantation for multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20091001

• [New treatment strategies for multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20091001

• Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.

  Annals of surgical oncology 20090901

• Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090901

• Superselective catheterization of the ophthalmic artery for intraarterial chemotherapy for retinoblastoma.

  Retina (Philadelphia, Pa.) 20090901

• Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma.

  Documenta ophthalmologica. Advances in ophthalmology 20090801

• Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090801

• pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.

  Leukemia & lymphoma 20090801

• Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090801

• Current treatment of AL amyloidosis.

  Haematologica 20090801

• Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.

  Anticancer research 20090801

• Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan.

  Molecular cancer therapeutics 20090801

• Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20090801

• Multiple myeloma.

  Lancet (London, England) 20090725

• Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090720

• [One hundred fifty autologous peripheral haemopoietic stem cell transplantations and their lessons].

  Orvosi hetilap 20090705

• Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney.

  Pediatric blood & cancer 20090701

• Brain amyloidoma with cerebral hemorrhage.

  The Journal of the American Osteopathic Association 20090701

• Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.

  European journal of haematology 20090601

• 2-(3-Aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides: a novel cluster of tumor-specific cytotoxins which reverse multidrug resistance.

  Bioorganic & medicinal chemistry 20090601

• Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion.

  Melanoma research 20090601

• Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.

  International journal of clinical oncology 20090601

• The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.

  Cancer 20090515

• Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts.

  Cancer research 20090515

• Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.

  Bone marrow transplantation 20090501

• Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.

  Bone marrow transplantation 20090501

• Design, cytotoxic and fluorescent properties of novel N-phosphorylalkyl substituted E,E-3,5-bis(arylidene)piperid-4-ones.

  European journal of medicinal chemistry 20090501

• Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.

  Annals of surgical oncology 20090501

• Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.

  Annals of surgical oncology 20090501

• Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.

  Cancer 20090501

• [Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].

  La Revue de medecine interne 20090501

• Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090501

• Hematology: Bortezomib in newly diagnosed multiple myeloma.

  Nature reviews. Clinical oncology 20090501

• [Stem cell therapy in multiple sclerosis: a clinical update].

  Zeitschrift fur Rheumatologie 20090501

• A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

  Journal of the American College of Surgeons 20090501

• Combination chemotherapy for high-risk gestational trophoblastic tumour.

  The Cochrane database of systematic reviews 20090415

• Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410

• Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.

  Blood 20090409

• ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.

  Blood 20090409

• Auer rod-like intracytoplasmic inclusions in multiple myeloma. A case report and review of the literature.

  International journal of laboratory hematology 20090401

• Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.

  Annals of hematology 20090401

• Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.

  Leukemia research 20090401

• Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial.

  Bone marrow transplantation 20090401

• Palifermin dose should be adjusted to different therapy regimens.

  Bone marrow transplantation 20090401

• delta-Aminolevulinate dehydratase activity and oxidative stress during melphalan and cyclophosphamide-BCNU-etoposide (CBV) conditioning regimens in autologous bone marrow transplantation patients.

  Pharmacological research 20090401

• Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090401

• Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.

  Melanoma research 20090401

• Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.

  Clinical lymphoma & myeloma 20090401

• Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment.

  Prescrire international 20090401

• Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma.

  Annals of hematology 20090301

• Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.

  Annals of hematology 20090301

• The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.

  British journal of haematology 20090301

• Mass selection of ions from beams using waveform isolation in radiofrequency quadrupoles.

  Analytical chemistry 20090301

• Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.

  British journal of haematology 20090301

• Clinicopathological investigation of a retinoblastoma eye enucleated after vitreous surgery with melphalan perfusion.

  Japanese journal of ophthalmology 20090301

• Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

  Leukemia & lymphoma 20090301

• Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine.

  Cancer research 20090215

• EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.

  Bone marrow transplantation 20090201

• The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.

  Experimental cell research 20090201

• New evidence in oncologic and cardiocirculatory medicine.

  Internal and emergency medicine 20090201

• Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation.

  American journal of hematology 20090201

• Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090201

• Treatment of multiple myeloma in the targeted therapy era.

  The Annals of pharmacotherapy 20090201

• Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial.

  Leukemia & lymphoma 20090201

• [Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].

  Vnitrni lekarstvi 20090201

• Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090120

• Febrile mucositis in haematopoietic SCT recipients.

  Bone marrow transplantation 20090101

• The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.

  Bone marrow transplantation 20090101

• Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.

  Bone marrow transplantation 20090101

• Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease.

  Immunologic research 20090101

• Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic Al amyloidosis.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20090101

• Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.

  International journal of hematology 20090101

• Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090101

• A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090101

• Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases.

  Internal medicine (Tokyo, Japan) 20090101

• Isolated limb infusion as a novel treatment for extensive plantar warts.

  Dermatology (Basel, Switzerland) 20090101

• Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.

  Journal of experimental & clinical cancer research : CR 20090101

• FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.

  Immunologic research 20090101

• The design, synthesis and anticancer activity of new nitrogen mustard derivatives of natural indole phytoalexin 1-methoxyspirobrassinol.

  Neoplasma 20090101

• Multiple myeloma with a variant Burkitt-type translocation, t(2;8)(p12;q24), associated with hyperammonemia.

  Internal medicine (Tokyo, Japan) 20090101

• Further progress in the treatment of multiple myeloma?

  The National medical journal of India 20090101

• In vitro cytotoxicity study of oxaziridines generated after chlordiazepoxide, demoxepam, and desmethylchlordiazepoxide UV irradiation.

  Drug and chemical toxicology 20090101

• Standard therapy of advanced Hodgkin lymphoma.

  Hematology. American Society of Hematology. Education Program 20090101

• The importance of complete response in outcomes in myeloma.

  Cancer journal (Sudbury, Mass.) 20090101

• Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

  Cancer journal (Sudbury, Mass.) 20090101

• Evolving role of novel agents for maintenance therapy in myeloma.

  Cancer journal (Sudbury, Mass.) 20090101

• Future novel single agent and combination therapies.

  Cancer journal (Sudbury, Mass.) 20090101

• Combined therapy with disintegrin and melphalan as a new strategy in inhibition of endometrial cancer cell line (Ishikawa) growth.

  Folia histochemica et cytobiologica 20090101

• Bortezomib plus melphalan and prednisone for multiple myeloma.

  The New England journal of medicine 20081211

• Bortezomib plus melphalan and prednisone for multiple myeloma.

  The New England journal of medicine 20081211

• Bortezomib plus melphalan and prednisone for multiple myeloma.

  The New England journal of medicine 20081211

• A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.

  Pediatric transplantation 20081201

• Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.

  Archives of toxicology 20081201

• Nuclear organization of PML bodies in leukaemic and multiple myeloma cells.

  Leukemia research 20081201

• The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.

  Leukemia 20081201

• Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.

  International journal of oncology 20081201

• Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma.

  Journal of pediatric surgery 20081201

• Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20081201

• [Papilledema as an indicator of POEMS syndrome].

  Archivos de la Sociedad Espanola de Oftalmologia 20081201

• Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.

  Dermatology online journal 20081115

• Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.

  Journal of medicinal chemistry 20081113

• Outcomes following isolated limb infusion for melanoma. A 14-year experience.

  Annals of surgical oncology 20081101

• Frontline treatment of multiple myeloma in elderly patients.

  Blood reviews 20081101

• Separation and identification of trinucleotide-melphalan adducts from enzymatically digested DNA using HPLC-ESI-MS.

  Analytical and bioanalytical chemistry 20081101

• Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.

  Cancer 20081101

• Advances in therapy of multiple myeloma.

  Current opinion in oncology 20081101

• p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

  Neoplasia (New York, N.Y.) 20081101

• Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

  Blood 20081015

• A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.

  Blood 20081001

• Isolated limb infusion for advanced soft tissue sarcoma of the extremity.

  Annals of surgical oncology 20081001

• Myelomatous meningitis.

  European journal of haematology 20081001

• Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.

  International journal of hematology 20081001

• Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.

  British journal of haematology 20081001

• Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells.

  Oncology reports 20081001

• [Treatment for multiple myeloma: current status and future strategy in Japan].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001

• Cisplatin abrogates the geldanamycin-induced heat shock response.

  Molecular cancer therapeutics 20081001

• Role of thalidomide in previously untreated patients with multiple myeloma.

  Expert review of anticancer therapy 20081001

• High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.

  Leukemia & lymphoma 20081001

• Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.

  Journal of Korean medical science 20081001

• Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.

  European journal of medicinal chemistry 20080901

• Supplementation of melatonin protects human lymphocytes in vitro from the genotoxic activity of melphalan.

  Mutagenesis 20080901

• Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.

  International journal of hematology 20080901

• Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.

  Bone marrow transplantation 20080901

• Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients.

  Bone marrow transplantation 20080901

• Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis.

  Haematologica 20080901

• Treatment of Hodgkin lymphoma: the past, present, and future.

  Nature clinical practice. Oncology 20080901

• Erythrophagocytic multiple myeloma in a cat.

  Veterinary clinical pathology 20080901

• Non-secretory myeloma: a rare variant of multiple myeloma.

  Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20080901

• Update on recent developments for patients with newly diagnosed multiple myeloma.

  Annals of the New York Academy of Sciences 20080901

• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  The New England journal of medicine 20080828

• Treatment of myeloma--are we making progress?

  The New England journal of medicine 20080828

• A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.

  Ophthalmology 20080801

• Histiocytic sarcoma localised in the thyroid: a case report.

  Annals of hematology 20080801

• Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

  Annals of hematology 20080801

• Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome.

  Bone marrow transplantation 20080801

• Complete and durable remission in a patient with life-threatening scleromyxedema treated with high-dose melphalan and BU with auto-SCT.

  Bone marrow transplantation 20080801

• Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.

  Annals of surgical oncology 20080801

• Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy.

  Bone marrow transplantation 20080801

• A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse model.

  Pigment cell & melanoma research 20080801

• Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.

  Hematology (Amsterdam, Netherlands) 20080801

• Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.

  Blood 20080715

• Alkylating agents induce activation of NFkappaB in multiple myeloma cells.

  Leukemia research 20080701

• Increased chemosensitivity and elevated reactive oxygen species are mediated by glutathione reduction in glutamine deprived neuroblastoma cells.

  Journal of cancer research and clinical oncology 20080701

• Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.

  Annals of surgical oncology 20080701

• Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080701

• Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080701

• Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.

  Cancer investigation 20080701

• The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

  Investigational new drugs 20080601

• Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

  Leukemia 20080601

• Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.

  Haematologica 20080601

• E,E-2-Benzylidene-6-(nitrobenzylidene)cyclohexanones: syntheses, cytotoxicity and an examination of some of their electronic, steric, and hydrophobic properties.

  Bioorganic & medicinal chemistry 20080601

• Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080601

• Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080601

• In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080601

• [Treatment strategy for POEMS syndrome].

  Brain and nerve = Shinkei kenkyu no shinpo 20080601

• Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma.

  Clinical lymphoma & myeloma 20080601

• [Treatment of myeloma in the elderly].

  Bulletin du cancer 20080528

• Possible chemical mechanisms underlying the antitumor activity of S-deoxyleinamycin.

  Bioorganic & medicinal chemistry letters 20080515

• 1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.

  Bioorganic & medicinal chemistry 20080515

• Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.

  Bioorganic & medicinal chemistry 20080515

• Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.

  Cancer research 20080515

• Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080501

• Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects.

  Clinical pharmacology and therapeutics 20080501

• Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion.

  Annals of surgical oncology 20080501

• Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma.

  Molecular therapy : the journal of the American Society of Gene Therapy 20080501

• The European approach to in-transit melanoma lesions.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20080501

• Future directions in regional treatment strategies for melanoma and sarcoma.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20080501

• Urinary cytology in multiple myeloma.

  Cytopathology : official journal of the British Society for Clinical Cytology 20080401

• Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives.

  European journal of medicinal chemistry 20080401

• Effects of intraocular irrigation with melphalan on rabbit retinas during vitrectomy.

  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20080401

• Small-molecule based delivery systems for alkylating antineoplastic compounds.

  ChemMedChem 20080401

• High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.

  Bone marrow transplantation 20080401

• Symptom burden after autologous stem cell transplantation for multiple myeloma.

  Cancer 20080401

• Thromboembolic events with lenalidomide-based therapy for multiple myeloma.

  Cancer 20080401

• Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.

  Pediatric blood & cancer 20080401

• Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.

  British journal of haematology 20080401

• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.

  Haematologica 20080401

• Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards.

  Chemical research in toxicology 20080401

• Potential role of a mismatched HLA-specific CTL clone developed pre-transplant in graft rejection following cord blood transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080401

• Hypercalcemia induced by 13 cis-retinoic acid in patients with neuroblastoma.

  Pediatrics international : official journal of the Japan Pediatric Society 20080401

• Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.

  Pediatric blood & cancer 20080301

• Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.

  European journal of haematology 20080301

• Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations.

  Annals of surgical oncology 20080301

• A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.

  Haematologica 20080301

• Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells.

  Haematologica 20080301

• Making quality-of-life results more meaningful for clinicians.

  Lancet (London, England) 20080301

• [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080301

• A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.

  Journal of pediatric hematology/oncology 20080301

• Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?

  Nature clinical practice. Oncology 20080201

• Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

  Leukemia 20080201

• Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen.

  Bone marrow transplantation 20080201

• Perspectives in treatment of AL amyloidosis.

  British journal of haematology 20080201

• Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

  Haematologica 20080201

• A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.

  Oncogene 20080131

• High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080110

• Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.

  Cancer chemotherapy and pharmacology 20080101

• Cytotoxic 3,5-bis(benzylidene)piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells.

  European journal of medicinal chemistry 20080101

• Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms.

  Leukemia research 20080101

• Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells.

  Journal of cellular biochemistry 20080101

• BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.

  Annals of hematology 20080101

• Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

  Blood cells, molecules & diseases 20080101

• Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.

  Blood 20080101

• Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080101

• Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.

  European journal of haematology 20080101

• Amyloidosis and vascular thrombosis.

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20080101

• Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.

  Pediatric hematology and oncology 20080101

• Necrobiotic xanthogranuloma occurring in an eyelid scar.

  Orbit (Amsterdam, Netherlands) 20080101

• Granulocytic sarcoma in a patient with essential thrombocythemia presented as acute spinal cord compression--case report and review of the literature.

  Clinical neuropathology 20080101

• Systemic lupus erythematosus and multiple myeloma: an uncommon association. Two cases and literature review.

  Clinical and experimental rheumatology 20080101

• [Management of immune suppression in systemic diseases affecting the kidney].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

• [Megachemotherapy and autologous stem cell transplantation in children with Ewing sarcoma - Polish experience].

  Medycyna wieku rozwojowego 20080101

• Refractory multiple myeloma treated with homoharringtonine: report of two cases.

  Annals of hematology 20071201

• Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.

  American journal of hematology 20071201

• Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.

  Bone marrow transplantation 20071201

• [Therapy of multiple myeloma: indications and options].

  Der Internist 20071201

• Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20071201

• Clinical updates and nursing considerations for patients with multiple myeloma.

  Clinical journal of oncology nursing 20071201

• Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.

  Current treatment options in oncology 20071201

• Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.

  Leukemia & lymphoma 20071201

• [Renal disease in multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• [POEMS syndrome: monoclonal plasma cell disorder with polyneuropathy].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• [Chemotherapy for multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• [Role of bortezomib in the treatment of multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation.

  Best practice & research. Clinical haematology 20071201

• [Synthesis and antitumor activity of benzoic nitrogen mustard derivatives].

  Yao xue xue bao = Acta pharmaceutica Sinica 20071201

• Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20071101

• Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

  Blood 20071101

• Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.

  Bone marrow transplantation 20071101

• Management of multiple myeloma: the changing landscape.

  Blood reviews 20071101

• Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20071101

• Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20071101

• Necrobiotic xanthogranuloma with paraproteinemia successfully treated with melphalan, prednisolone and skin graft.

  The Journal of dermatology 20071101

• Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature.

  Leukemia & lymphoma 20071101

• Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

  Transplantation proceedings 20071101

• Bortezomib inhibits osteoclast activity in patients with multiple myeloma.

  Clinical lymphoma & myeloma 20071101

• [Diagnosis and therapy for multiple myeloma: Practice guidelines].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20071010

• A new standard of care for elderly patients with myeloma.

  Lancet (London, England) 20071006

• Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

  Lancet (London, England) 20071006

• Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.

  Clinical pharmacology and therapeutics 20071001

• [New treatment of multiple myeloma].

  La Revue de medecine interne 20071001

• Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.

  Bone marrow transplantation 20071001

• Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.

  Leukemia 20071001

• Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071001

• Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

  British journal of haematology 20071001

• Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

  British journal of haematology 20071001

• [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071001

• High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.

  Seminars in hematology 20071001

• Autologous stem cell transplantation for chronic lymphocytic leukemia.

  Seminars in hematology 20071001

• Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.

  International journal of hematology 20071001

• A concurrence of light and heavy chain deposition disease and diabetic nephropathy.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20071001

• Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.

  Current hematologic malignancy reports 20071001

• E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones: a topographical study of some novel potent cytotoxins.

  Bioorganic & medicinal chemistry 20070901

• High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20070901

• Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070901

• Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).

  Pediatric hematology and oncology 20070901

• The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.

  Molecular cancer therapeutics 20070901

• Rapidly reversible hydrophobization: an approach to high first-pass drug extraction.

  Chemistry & biology 20070901

• Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.

  Clinical nephrology 20070901

• High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.

  Leukemia research 20070801

• Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?

  Pediatric blood & cancer 20070801

• Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).

  Leukemia 20070801

• Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.

  British journal of haematology 20070801

• [Nutritional pathway for autologous stem cell transplantation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].

  Deutsche medizinische Wochenschrift (1946) 20070801

• Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.

  European journal of pharmacology 20070730

• Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.

  International journal of radiation oncology, biology, physics 20070715

• Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma.

  Pharmaceutical research 20070701

• Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity.

  Annals of surgical oncology 20070701

• Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.

  British journal of haematology 20070701

• Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan.

  Pharmacogenetics and genomics 20070701

• Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.

  British journal of haematology 20070701

• Melphalan and its role in the management of patients with multiple myeloma.

  Expert review of anticancer therapy 20070701

• Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.

  International journal of hematology 20070701

• Multiple myeloma: a ten year study of survival and therapy in a developing nation.

  JPMA. The Journal of the Pakistan Medical Association 20070701

• Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070610

• Extended right trisegmentectomy using in situ hypothermic perfusion with modified HTK solution for a large intrahepatic cholangiocarcinoma.

  Journal of surgical oncology 20070601

• Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.

  The Journal of pharmacology and experimental therapeutics 20070601

• Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.

  Hematology (Amsterdam, Netherlands) 20070601

• 3-(3,4,5-Trimethoxyphenyl)-1-oxo-2-propene: a novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity.

  Bioorganic & medicinal chemistry 20070515

• Association of acquired von Willebrand syndrome with AL amyloidosis.

  American journal of hematology 20070501

• Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.

  Gynecologic oncology 20070501

• Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis.

  American journal of hematology 20070501

• Allogeneic bone marrow transplantation for Pearson's syndrome.

  Bone marrow transplantation 20070501

• Amidine analogues of melphalan: synthesis, cytotoxic activity, and DNA binding properties.

  Archiv der Pharmazie 20070501

• Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.

  Molecular cancer therapeutics 20070501

• A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.

  Leukemia & lymphoma 20070501

• Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

  Haematologica 20070501

• [The standard treatments for patients with hematological malignancies in Japan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070501

• The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.

  Transplantation proceedings 20070501

• Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.

  The journal of supportive oncology 20070501

• High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.

  Pediatric blood & cancer 20070401

• Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion.

  Cancer immunology, immunotherapy : CII 20070401

• Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.

  Blood 20070401

• Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.

  Annals of surgical oncology 20070401

• Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.

  Annals of hematology 20070401

• Aneugenic potential of the nitrogen mustard analogues melphalan, chlorambucil and p-N,N-bis(2-chloroethyl)aminophenylacetic acid in cell cultures in vitro.

  Mutation research 20070401

• Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells.

  Anti-cancer drugs 20070401

• Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

  Experimental hematology 20070401

• Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070401

• Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070401

• Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology.

  Annals of surgery 20070401

• [Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation].

  Ai zheng = Aizheng = Chinese journal of cancer 20070401

• Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy.

  Hematology (Amsterdam, Netherlands) 20070401

• Amyloidosis: a changing clinical perspective.

  Hematology (Amsterdam, Netherlands) 20070401

• Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.

  Leukemia & lymphoma 20070401

• Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.

  Haematologica 20070401

• Palifermin and palmar-plantar erythrodysesthesia.

  British journal of haematology 20070301

• High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.

  Bone marrow transplantation 20070301

• Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate.

  European journal of neurology 20070301

• A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.

  Molecular cancer therapeutics 20070301

• Multiple myeloma therapies.

  Nature reviews. Drug discovery 20070301

• Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.

  Cancer research 20070215

• Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.

  American journal of hematology 20070201

• Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).

  Blood 20070201

• The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.

  Annals of hematology 20070201

• Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan.

  Cancer chemotherapy and pharmacology 20070201

• Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.

  Annals of surgical oncology 20070201

• Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.

  Radiology 20070201

• Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.

  Bone marrow transplantation 20070201

• Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070201

• Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.

  Onkologie 20070201

• Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20070201

• Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.

  European journal of haematology 20070201

• Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.

  Leukemia & lymphoma 20070201

• Managing systemic light-chain amyloidosis.

  Journal of the National Comprehensive Cancer Network : JNCCN 20070201

• [Recent progress in the treatment of multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20070201

• [79 year old male with constitutional syndrome and hepatomegaly].

  Revista clinica espanola 20070201

• [What is your diagnosis? Neutropenic colitis (neutropenic typhlitis)].

  Praxis 20070124

• The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070115

• Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.

  Blood 20070101

• Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds.

  European journal of medicinal chemistry 20070101

• Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction.

  Contributions to nephrology 20070101

• Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.

  Contributions to nephrology 20070101

• Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.

  British journal of haematology 20070101

• Outpatient high-dose melphalan in multiple myeloma patients.

  Transfusion 20070101

• [Four cases of therapy-related leukemia in multiple myeloma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• Double unrelated reduced-intensity umbilical cord blood transplantation in adults.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070101

• A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.

  British journal of haematology 20070101

• 48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.

  Clinical lymphoma & myeloma 20070101

• Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.

  Haematologica 20070101

• High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.

  La Tunisie medicale 20070101

• Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

  Anticancer research 20070101

• [Treatment and survival of multiple myeloma patients on programmed hemodialysis].

  Terapevticheskii arkhiv 20070101

• Survival benefit with GM-CSF use after high-dose chemotherapy in high-risk breast cancer.

  Tumori 20070101

• High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.

  American journal of hematology 20061201

• Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma.

  Hematological oncology 20061201

• Four-color flow cytometric analysis of myeloma plasma cells.

  American journal of clinical pathology 20061201

• Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061201

• Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061201

• Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061201

• Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061201

• Therapy and management of systemic AL (primary) amyloidosis.

  Swiss medical weekly 20061111

• Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.

  European journal of haematology 20061101

• [Bilateral serous detachment of the neurosensory retina and retinal pigment epithelium with rip of the peripheral pigment epithelium].

  Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 20061101

• Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells.

  Experimental hematology 20061101

• FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma.

  Clinical nuclear medicine 20061101

• Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.

  The Lancet. Oncology 20061101

• What's wrong with this patient? Primary systemic amyloidosis.

  RN 20061101

• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

  Blood 20061001

• Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.

  Annals of hematology 20061001

• Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.

  European journal of haematology 20061001

• Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.

  British journal of haematology 20061001

• Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

  British journal of haematology 20061001

• The effect of intracellular ascorbate on the susceptibility of HL60 and Jurkat cells to chemotherapy agents.

  Apoptosis : an international journal on programmed cell death 20061001

• Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.

  Bone marrow transplantation 20061001

• Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer.

  Bone marrow transplantation 20061001

• Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.

  Bone marrow transplantation 20061001

• Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.

  British journal of haematology 20061001

• Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

  International journal of hematology 20061001

• Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues.

  Journal of medicinal chemistry 20060921

• [Recent progress in diagnosis of and therapy for multiple myeloma].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060910

• Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20060901

• Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.

  British journal of haematology 20060901

• Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.

  Bone marrow transplantation 20060901

• Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy.

  Bone marrow transplantation 20060901

• Myelomatous pleural effusion.

  The Journal of the Association of Physicians of India 20060901

• Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.

  European journal of medical research 20060830

• Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060820

• Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.

  DNA repair 20060813

• High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060801

• A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.

  Annals of surgical oncology 20060801

• A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060801

• Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.

  Journal of thrombosis and haemostasis : JTH 20060801

• Amyloid myopathy presenting with rhabdomyolysis: evidence of complement activation.

  Neuromuscular disorders : NMD 20060801

• Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma.

  International journal of hematology 20060801

• Successful treatment of a patient with POEMS syndrome by tandem high-dose chemotherapy with autologous CD34+ purged stem cell rescue.

  International journal of hematology 20060801

• Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.

  Transfusion 20060801

• Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.

  Leukemia & lymphoma 20060801

• High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

  Leukemia & lymphoma 20060801

• Role of B-type natriuretic peptide in cardiovascular state monitoring in a hemodialysis patient with primary amyloidosis.

  The International journal of artificial organs 20060801

• Novel amidine analogue of melphalan as a specific multifunctional inhibitor of growth and metabolism of human breast cancer cells.

  Biochemical pharmacology 20060728

• A singular case of multiple myeloma and primary biliary cirrhosis strictly associated in pathogenesis and response to alkylating therapy.

  American journal of hematology 20060701

• Epistaxis and severe weakness in a patient with multiple myeloma. Therapy-related acute myeloid leukemia, pure erythroid leukemia.

  Archives of pathology & laboratory medicine 20060701

• [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060701

• Advances in the treatment of elderly patients with multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20060701

• Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.

  Blood 20060615

• Serial transplantation resulting in tolerance to an unrelated cord blood graft.

  Transplantation 20060615

• Unrelated donor cord blood transplantation for childhood severe aplastic anemia after a modified conditioning.

  Pediatric transplantation 20060601

• Possibilities of improving the parameters of hyperthermia in regional isolated limb perfusion using epidural bupivacaine and accurate temperature measurement of the three layers of limb tissue.

  Melanoma research 20060601

• The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

  Cancer research 20060601

• Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20060601

• Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.

  Clinical therapeutics 20060601

• [Plasmacytoma with multiple hypervascular lesions revealed by angiography in a patient with multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060601

• [White blood cell lysis syndrome after autologous peripheral blood stem cell transplantation in the treatment of renal AL amyloidosis. Case report].

  Revista medica de Chile 20060601

• Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.

  Cancer 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.

  Haematologica 20060501

• Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060501

• Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.

  International journal of hematology 20060501

• Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.

  International journal of hematology 20060501

• Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.

  Clinical lymphoma & myeloma 20060501

• [Procedure for determination of individual sensitivity to antitumor drugs].

  Klinicheskaia laboratornaia diagnostika 20060501

• Interpreting cell cycle effects of drugs: the case of melphalan.

  Cancer chemotherapy and pharmacology 20060401

• Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).

  Journal of cancer research and clinical oncology 20060401

• Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

  European journal of haematology 20060401

• Long-term complete remission in IgD-myeloma.

  European journal of haematology 20060401

• Thalidomide for the treatment of leptomeningeal multiple myeloma.

  European journal of haematology 20060401

• Quantitative determination of melphalan DNA adducts using HPLC - inductively coupled mass spectrometry.

  Journal of mass spectrometry : JMS 20060401

• Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.

  American journal of hematology 20060401

• Thalidomide gives food for thought in multiple myeloma.

  The Lancet. Oncology 20060401

• Circulating levels and clinical significance of soluble CD86 in myeloma patients.

  British journal of haematology 20060401

• Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20060401

• Progress in the treatment of multiple myeloma.

  Lancet (London, England) 20060311

• Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

  Lancet (London, England) 20060311

• Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

  The New England journal of medicine 20060309

• The changing landscape of myeloma therapy.

  The New England journal of medicine 20060309

• Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20060301

• Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.

  Annals of hematology 20060301

• Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.

  Bone marrow transplantation 20060301

• Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.

  Bone marrow transplantation 20060301

• Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature.

  International journal of dermatology 20060301

• [Comparison of the long term results between two conditioning regimens MCC and BuCy in chronic myelocytic leukemia after allogeneic stem cell transplantation].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20060301

• Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060220

• Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060220

• Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.

  Blood 20060215

• Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.

  Cancer research 20060215

• Successful autologous peripheral blood stem cell harvest and transplant in a patient with cold agglutinins.

  Bone marrow transplantation 20060201

• Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.

  Leukemia 20060201

• Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient.

  Leukemia & lymphoma 20060201

• Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.

  Haematologica 20060201

• Chemotherapy and radiotherapy causing radiation myelopathy: what is to blame?

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20060201

• Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060120

• Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.

  Cancer 20060115

• [Prognostic factors and new treatments of multiple myeloma].

  La Revue du praticien 20060115

• [Haemorrhagic diathesis as an early symptom of systemic amyloidosis].

  Deutsche medizinische Wochenschrift (1946) 20060105

• Sequential, cycling maintenance therapy for post transplant multiple myeloma.

  Bone marrow transplantation 20060101

• Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.

  Bone marrow transplantation 20060101

• Trial of amifostine in autologous stem cell transplant.

  Bone marrow transplantation 20060101

• Thyroid hormone and insulin-like growth factor-I in patients with multiple myeloma treated with melphalan and prednisone.

  Archives of medical research 20060101

• Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients.

  American journal of hematology 20060101

• Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.

  Japanese journal of clinical oncology 20060101

• High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control.

  Acta haematologica 20060101

• Evaluation of chemosensitivity of human bone marrow stromal cells--differences between common chemotherapeutic drugs.

  Anticancer research 20060101

• [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060101

• Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

  Bioconjugate chemistry 20060101

• Treatment of multiple myeloma: an emphasis on new developments.

  Annals of medicine 20060101

• Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.

  BMC cancer 20060101

• Inhibition of homologous recombination repair with Pentoxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation.

  Radiation oncology (London, England) 20060101

• Hospital in the home (HITH) care following autologous stem cell transplantation for lymphoma and multiple myeloma.

  The Australian journal of advanced nursing : a quarterly publication of the Royal Australian Nursing Federation 20060101

• [A case of primary amyloidosis].

  Klinicheskaia meditsina 20060101

• Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome.

  Acta oncologica (Stockholm, Sweden) 20060101

• Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.

  Journal of experimental therapeutics & oncology 20060101

• Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.

  Journal of veterinary internal medicine 20060101

• Primary cardiac amyloidosis with 20-year survival.

  Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 20060101

• Selected hypoxic stop-flow perfusions: indication and limits.

  Tumori 20060101

• Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D.

  Journal of cutaneous medicine and surgery 20060101

• Management of multiple myeloma with bortezomib: experts review the data and debate the issues.

  Oncology 20060101

• ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

  Blood 20051201

• Factors useful for predicting survival of myeloma patients in everyday practice. A 10-year study of 148 patients older than 55 years.

  Joint, bone, spine : revue du rhumatisme 20051201

• Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.

  Haematologica 20051201

• Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.

  Archives of internal medicine 20051201

• Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR-mismatched bone marrow transplantation.

  Journal of pediatric hematology/oncology 20051201

• Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications.

  Molecular cancer therapeutics 20051201

• Localized amyloidosis: a survey of 35 French cases.

  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20051201

• Bortezomib-induced Sweet's syndrome.

  Haematologica 20051201

• New treatments for multiple myeloma.

  Oncology (Williston Park, N.Y.) 20051201

• Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

  Blood 20051115

• Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?

  Annals of hematology 20051101

• Thalidomide-associated thrombocytopenia.

  The Annals of pharmacotherapy 20051101

• Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.

  British journal of haematology 20051101

• Type III hyperlipoproteinemia with xanthomas and multiple myeloma.

  Journal of the American Academy of Dermatology 20051101

• [Successful rituximab treatment in a patient with refractory hairy cell leukemia-Japanese variant and suffering from acute respiratory distress].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20051101

• In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051015

• Multiple myeloma: the present and the future.

  The Medical journal of Australia 20051003

• High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.

  Annals of hematology 20051001

• Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.

  Cancer 20051001

• Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.

  Oncology reports 20051001

• First-line autologous stem cell transplantation in primary CNS lymphoma.

  European journal of haematology 20051001

• Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma.

  Pediatric transplantation 20051001

• Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft.

  Hematology (Amsterdam, Netherlands) 20051001

• Multiple myeloma: diagnosis and treatment.

  Mayo Clinic proceedings 20051001

• Plasma cell leukemia: case report of a rare and aggressive variant of multiple myeloma.

  JPMA. The Journal of the Pakistan Medical Association 20051001

• Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.

  Bone marrow transplantation 20050901

• Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.

  Free radical biology & medicine 20050901

• A case of monoclonal immunoglobulin light- and heavy-chain deposition disease exhibiting atypical deposition with fibrillary structures, successfully treated with chemotherapy.

  Clinical nephrology 20050901

• Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.

  Bone marrow transplantation 20050801

• High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050801

• Perspectives for combination therapy to overcome drug-resistant multiple myeloma.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20050801

• Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20050801

• Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20050801

• High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.

  British journal of haematology 20050801

• 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.

  British journal of haematology 20050801

• Focal and segmental glomerulosclerosis and plasma cell proliferative disorders.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20050801

• The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20050701

• Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.

  Bone marrow transplantation 20050701

• Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders.

  American journal of hematology 20050701

• Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome.

  American journal of hematology 20050701

• A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20050701

• Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.

  The Journal of thoracic and cardiovascular surgery 20050701

• Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.

  British journal of haematology 20050601

• Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.

  British journal of haematology 20050601

• Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.

  American journal of clinical oncology 20050601

• High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an 'Intergruppo Italiano Linfomi' randomized trial.

  Haematologica 20050601

• Current treatment options for myeloma.

  Expert opinion on pharmacotherapy 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20050601

• Autografting followed by rituximab for chemosensitive mantle cell lymphoma: a pilot study and literature review.

  Leukemia & lymphoma 20050601

• Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

  Leukemia & lymphoma 20050601

• Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.

  Annals of hematology 20050501

• Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.

  Bone marrow transplantation 20050501

• Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival.

  Bone marrow transplantation 20050501

• Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft.

  European journal of haematology 20050501

• Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes.

  Molecular immunology 20050501

• Plasma cell problems: Case 2. Extramedullary cardiac plasmacytoma presenting with cardiac tamponade.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050501

• Treatment of myeloma in patients not eligible for transplantation.

  Current treatment options in oncology 20050501

• The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.

  International journal of hematology 20050501

• Metabolism of melphalan by rat liver microsomal glutathione S-transferase.

  Chemico-biological interactions 20050415

• High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.

  Pediatric blood & cancer 20050401

• Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20050401

• Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050401

• Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20050401

• Five-month marrow aplasia in a child with refractory acute myeloid leukemia: successful management with continuous granulocyte support and reduced-intensity conditioning followed by matched unrelated bone marrow transplantation.

  Journal of pediatric hematology/oncology 20050401

• Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.

  Oncology (Williston Park, N.Y.) 20050401

• Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life.

  Blood 20050315

• The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration.

  Journal of immunology (Baltimore, Md. : 1950) 20050315

• Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.

  British journal of haematology 20050301

• Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.

  British journal of clinical pharmacology 20050301

• Multiple complications in multiple myeloma.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20050301

• Resolution of primary amyloidosis by melphalan and prednisolone: a case report.

  Clinical nephrology 20050301

• Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.

  Cancer 20050201

• Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.

  Pediatric transplantation 20050201

• Biological modifiers as cytoreductive therapy before stem cell transplant in previously untreated patients with multiple myeloma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050201

• Radiologic findings in primary pulmonary plasmacytoma.

  Journal of thoracic imaging 20050201

• Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.

  Annals of surgical oncology 20050201

• Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action.

  Journal of medicinal chemistry 20050127

• Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• Protective effect of quercetin and luteolin in human melanoma HMB-2 cells.

  Mutation research 20050103

• Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.

  Leukemia 20050101

• A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.

  Leukemia 20050101

• Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ('Yasmine').

  Bone marrow transplantation 20050101

• Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

  Annals of oncology : official journal of the European Society for Medical Oncology 20050101

• Evolution of hepatosplenic plasmacytoma in a patient with multiple myeloma receiving chemotherapy.

  American journal of hematology 20050101

• High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.

  European journal of cancer (Oxford, England : 1990) 20050101

• Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.

  Haematologica 20050101

• Implications of enzymatic, acidic and thermal hydrolysis of DNA on the occurrence of cross-linked melphalan DNA adducts.

  Rapid communications in mass spectrometry : RCM 20050101

• Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20050101

• High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.

  Journal of neuro-oncology 20050101

• Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan.

  Cancer investigation 20050101

• Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs.

  Molecular pharmaceutics 20050101

• The nitrogen mustard melphalan activates mitogen-activated phosphorylated kinases (MAPK), nuclear factor-kappaB and inflammatory response in lung epithelial cells.

  Journal of applied toxicology : JAT 20050101

• Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.

  Anticancer research 20050101

• Locoregional therapies of liver metastases in a rat CC531 coloncarcinoma model results in increased resistance to tumour rechallenge.

  Clinical & experimental metastasis 20050101

• Necrobiotic xanthogranuloma-rapid progression under treatment with melphalan.

  European journal of dermatology : EJD 20050101

• Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats.

  Acta cirurgica brasileira 20050101

• Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.

  Bone marrow transplantation 20041201

• VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.

  European journal of haematology 20041201

• Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.

  American journal of hematology 20041201

• High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

  British journal of haematology 20041201

• A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.

  Haematologica 20041201

• Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene.

  Journal of pediatric hematology/oncology 20041201

• Phase I study for poor-prognosis lymphoma: augmentation of the 'BEAM' regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.

  Seminars in oncology 20041201

• Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.

  Journal of the National Cancer Institute 20041103

• Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.

  American journal of surgery 20041101

• Conditioning regimen of melphalan, fludarabine and total body irradiation in unmanipulated HLA haploidentical stem cell transplantation based on feto-maternal tolerance.

  Internal medicine (Tokyo, Japan) 20041101

• [Systemic ALlambda amyloidosis associated with vascular fragility].

  Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20041101

• [Cutaneous plasmacytomas following treatment of IgA kappa multiple myeloma].

  Medicina clinica 20041030

• High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.

  Bone marrow transplantation 20041001

• A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.

  Leukemia 20041001

• Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.

  Bone marrow transplantation 20041001

• Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.

  Bone marrow transplantation 20041001

• Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20041001

• Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.

  British journal of haematology 20041001

• Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• [Multiple myeloma of the IgD-lambda type invading CNS].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20041001

• Design and synthesis of a nitrogen mustard derivative stabilized by apo-neocarzinostatin.

  Journal of medicinal chemistry 20040909

• In-transit melanoma: the role of alkylating-agent resistance in regional therapy.

  Journal of the American College of Surgeons 20040901

• The role of hyperthermia in regional alkylating agent chemotherapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040901

• The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.

  Haematologica 20040901

• 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.

  Haematologica 20040901

• [Soft tissue sarcoma: postoperative chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.

  Clinical lymphoma 20040901

• L-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter.

  Biochimica et biophysica acta 20040830

• Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.

  European journal of haematology 20040801

• A rare case of interstitial pneumonitis after tandem high-dose melphalan conditioning and autologous stem cell transplantation in multiple myeloma.

  European journal of haematology 20040801

• Modulation of resistance to regional chemotherapy in the extremity melanoma model.

  Surgery 20040801

• Caspase-11 is not necessary for chemotherapy-induced intestinal mucositis.

  DNA and cell biology 20040801

• Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.

  Breast (Edinburgh, Scotland) 20040801

• Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040715

• Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.

  Annals of hematology 20040701

• Deletion of 5q31 and 7q31 in patients with stable melphalan treated multiple myeloma.

  Cancer genetics and cytogenetics 20040701

• Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20040701

• Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.

  Bone marrow transplantation 20040701

• Adenine-containing DNA-DNA cross-links of antitumor nitrogen mustards.

  Chemical research in toxicology 20040701

• Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.

  Cancer 20040615

• Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.

  Cancer chemotherapy and pharmacology 20040601

• Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.

  Bone marrow transplantation 20040601

• High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission.

  Bone marrow transplantation 20040601

• Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia.

  Bone marrow transplantation 20040601

• Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.

  European journal of haematology 20040601

• Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.

  British journal of haematology 20040601

• Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.

  Blood 20040601

• Thrombotic microangiopathy (TMA) and stroke due to human herpesvirus-6 (HHV-6) reactivation in an adult receiving high-dose melphalan with autologous peripheral stem cell transplantation.

  American journal of hematology 20040601

• Guidelines on the diagnosis and management of AL amyloidosis.

  British journal of haematology 20040601

• Treatment of chronic lymphocytic leukaemia in three dogs with melphalan and prednisolone.

  The Journal of small animal practice 20040601

• Managing the patient with amyloidosis.

  Dermatology nursing 20040601

• High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.

  The Korean journal of internal medicine 20040601

• Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.

  Biochemistry 20040525

• Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells.

  Cancer research 20040515

• Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.

  Journal of medicinal chemistry 20040506

• Endogenously generated hydrogen peroxide is required for execution of melphalan-induced apoptosis as well as oxidation and externalization of phosphatidylserine.

  Chemical research in toxicology 20040501

• Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents.

  Neoplasia (New York, N.Y.) 20040501

• [Amyloidosis].

  Nihon rinsho. Japanese journal of clinical medicine 20040501

• Tandem transplants in the treatment of multiple myeloma. Pro.

  Clinical advances in hematology & oncology : H&O 20040501

• Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

  Blood 20040415

• Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.

  Annals of hematology 20040401

• Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.

  Bone marrow transplantation 20040401

• Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.

  Bone marrow transplantation 20040401

• Structural characterization of melphalan modified 2'-oligodeoxynucleotides by miniaturized LC-ES MS/MS.

  Journal of the American Society for Mass Spectrometry 20040401

• Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides.

  Human gene therapy 20040401

• Early response to therapy and survival in multiple myeloma.

  British journal of haematology 20040401

• Isolated hepatic perfusion: experimental evidence and clinical utility.

  The Surgical clinics of North America 20040401

• Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.

  European journal of haematology 20040401

• The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma.

  International journal of clinical oncology 20040401

• A primary hepatic plasma cell tumor in a dog.

  The Journal of veterinary medical science 20040401

• [Early treatment of a Bence-Jones-kappa-light-chain-paraproteinemia].

  Der Internist 20040401

• High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.

  Leukemia & lymphoma 20040401

• Primary systemic amyloidosis.

  The Journal of the Association of Physicians of India 20040401

• Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

  The New England journal of medicine 20040325

• Multiple myeloma.

  Lancet (London, England) 20040313

• Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.

  Leukemia research 20040301

• Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.

  Oncology reports 20040301

• Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences.

  European journal of haematology 20040301

• Metaiodobenzylguanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma.

  Annals of surgical oncology 20040301

• [A case of amyloidosis of the large intestine which showed remarkable calcification of the intestinal wall].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20040301

• [Granulocyte-colony stimulating factor-producing myeloma with clinical manifestations mimicking chronic neutrophilic leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20040301

• Annexin-I expression modulates drug resistance in tumor cells.

  Biochemical and biophysical research communications 20040206

• High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.

  Bone marrow transplantation 20040201

• Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity.

  Journal of immunology (Baltimore, Md. : 1950) 20040201

• Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.

  International journal of hematology 20040201

• Hb H disease and multiple myeloma.

  Hemoglobin 20040201

• [Multiple myeloma and HIV infection: report of 3 cases].

  Revue medicale de Liege 20040201

• Treatment of multiple myeloma.

  Blood 20040101

• High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.

  Bone marrow transplantation 20040101

• Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report.

  Gynecologic oncology 20040101

• Multiple myeloma presenting with widespread osteosclerotic lesions.

  Joint, bone, spine : revue du rhumatisme 20040101

• [Synthesis and properties of fluorescently-labelled triglyceride, derivative of the antineoplastic agent sarcolysin].

  Bioorganicheskaia khimiia 20040101

• Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma.

  The hematology journal : the official journal of the European Haematology Association 20040101

• High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors.

  Journal of neuro-oncology 20040101

• Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines.

  Anti-cancer drugs 20040101

• Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line.

  Journal of proteome research 20040101

• Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Thrombectomy discloses intravascular growth of chondroid liposarcoma mimicking a long distance vena cava thrombosis.

  In vivo (Athens, Greece) 20040101

• Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Multiple myeloma associated with CD4+ large granular lymphocytic leukemia: a possible causal relationship.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis -platin, Tamoxifen, Melphalan, Betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside.

  Glycoconjugate journal 20040101

• Impaired PBPC collection in patients with myeloma after high-dose melphalan.

  Cytotherapy 20040101

• Complete remission of previously intractable peripheral cutaneous T-cell lymphoma of the lower extremity using isolated hyperthermic limb perfusion with melphalan (1-phenylalanine mustard).

  Cancer investigation 20040101

• Cardiac amyloidosis--an update.

  Indian heart journal 20040101

• [Primary amyloidosis associated to severe factor X deficiency].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20040101

• [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].

  Przeglad lekarski 20040101

• [Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].

  Voprosy onkologii 20040101

• High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.

  Annals of oncology : official journal of the European Society for Medical Oncology 20031201

• Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

  Bone marrow transplantation 20031201

• Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.

  Haematologica 20031201

• Fibrillary glomerulonephritis associated with essential thrombocytosis.

  Clinical and experimental nephrology 20031201

• [An autopsy case of the hepatocellular carcinoma associated with multiple myeloma which developed fatal massive hemolysis due to the Clostridium perfringens septicemia following TAE].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20031201

• Eye-preservation treatment of retinoblastoma with vitreous seeding.

  Japanese journal of clinical oncology 20031201

• Evaluation of intensive chemotherapy in AL amyloidosis: usefulness of flow cytometric analysis of plasma cells in bone marrow.

  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20031201

• Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias.

  Journal of experimental & clinical cancer research : CR 20031201

• Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.

  Blood 20031115

• Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031115

• Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

  Cancer research 20031115

• Proline analogue of melphalan as a prodrug susceptible to the action of prolidase in breast cancer MDA-MB 231 cells.

  Farmaco (Societa chimica italiana : 1989) 20031101

• In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).

  Bone marrow transplantation 20031101

• The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma.

  Yonsei medical journal 20031030

• Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.

  European journal of medical research 20031022

• Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.

  Blood 20031001

• Studies with cytotoxic agents suggest that apoptosis is not a major determinant of clonogenic death in neuroblastoma cells.

  European journal of cancer (Oxford, England : 1990) 20031001

• High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study.

  Journal of Korean medical science 20031001

• Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue.

  Biomedical chromatography : BMC 20031001

• [Diagnosis of multiple myeloma by demonstrating plasma cells in bronchoalveolar lavage].

  Deutsche medizinische Wochenschrift (1946) 20030919

• Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.

  Bone marrow transplantation 20030901

• Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients.

  British journal of haematology 20030901

• Unusual IgM-secreting multiple myeloma in a dog.

  Journal of the American Veterinary Medical Association 20030901

• Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.

  Annals of hematology 20030901

• [Mini-transplantation from cord blood].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• Evaluation of relative anti-myeloma activity of high-dose melphalan followed by the first peripheral blood stem cell transplantation, as compared with the second transplantation, and to VAD chemotherapy.

  Transplantation proceedings 20030901

• Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines.

  Molecular cancer therapeutics 20030901

• A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.

  Clinical lymphoma 20030901

• High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030815

• Testicular plasmacytoma with bone dissemination without medullary plasmacytosis.

  Annals of hematology 20030801

• Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.

  Bone marrow transplantation 20030801

• Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030801

• A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.

  Journal of mathematical biology 20030801

• Primary amyloidosis with pulmonary involvement which presented exudative pleural effusion and high fever.

  Internal medicine (Tokyo, Japan) 20030801

• Oxidation of mitoxantrone by lactoperoxidase.

  Biochimica et biophysica acta 20030730

• Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

  Blood 20030715

• Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.

  International journal of cancer 20030710

• Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030701

• A 65-year-old man with early renal allograft dysfunction.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20030701

• Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20030701

• BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.

  Leukemia & lymphoma 20030701

• Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.

  Journal of drug targeting 20030701

• Stiff heart syndrome.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20030624

• Chemical synthesis and cytotoxicity of dihydroxylated cyclopentenone analogues of neocarzinostatin chromophore.

  Bioorganic & medicinal chemistry letters 20030616

• Oral melphalan as a treatment for platinum-resistant ovarian cancer.

  British journal of cancer 20030616

• Melphalan antitumor efficacy and hepatotoxicity: the effect of variable infusion duration in the hepatic artery.

  The Journal of pharmacology and experimental therapeutics 20030601

• Intraocular extramedullary plasmacytoma in a cat.

  Veterinary ophthalmology 20030601

• High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.

  Cancer 20030601

• Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.

  Bone marrow transplantation 20030601

• High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601

• Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.

  Annals of surgical oncology 20030601

• Extramedullary liver plasmacytoma a rare presentation.

  Leukemia & lymphoma 20030601

• 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients.

  Leukemia & lymphoma 20030601

• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  The New England journal of medicine 20030508

• [Ascites as the sole clinical manifestation in a patient with nodular regenerative hyperplasia].

  Gastroenterologia y hepatologia 20030501

• Management of multiple myeloma: a systematic review and critical appraisal of published studies.

  The Lancet. Oncology 20030501

• Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.

  Annals of surgical oncology 20030501

• A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia.

  Human pathology 20030501

• Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030415

• Pharmacotherapy of multiple myeloma: an economic perspective.

  Expert opinion on pharmacotherapy 20030401

• Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.

  Bone marrow transplantation 20030401

• Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.

  Cancer biotherapy & radiopharmaceuticals 20030401

• Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.

  Blood 20030315

• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

  Blood 20030315

• Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

  Blood 20030315

• Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.

  Blood 20030301

• [Bacteremia due to Capnocytophaga spp.: two cases].

  Enfermedades infecciosas y microbiologia clinica 20030301

• Regional isolated perfusion of extremities for melanoma: now a 26-year experience with drugs other than L-phenylalanine mustard.

  Plastic and reconstructive surgery 20030301

• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030301

• Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype.

  British journal of haematology 20030301

• Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells.

  Cancer immunology, immunotherapy : CII 20030301

• BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20030301

• Quantification of DNA adducts in individual cells by immunofluorescence: effects of variation in DNA conformation.

  Experimental cell research 20030215

• Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.

  American journal of hematology 20030201

• [Foliculitis in a patient with Hodkins disease].

  Enfermedades infecciosas y microbiologia clinica 20030201

• [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030201

• Cytotoxic analogues of 2,6-bis(arylidene)cyclohexanones.

  European journal of medicinal chemistry 20030201

• High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.

  Bone marrow transplantation 20030201

• Idarubicin containing regimen in multiple myeloma: preliminary results of a pilot study using a modified 'TANDEM' transplant program.

  Leukemia & lymphoma 20030201

• Maintenance with pamidronate following first-line MP or VAD therapy in multiple myeloma.

  Leukemia & lymphoma 20030201

• Multiple myeloma associated with systemic lupus erythematosus.

  Leukemia & lymphoma 20030201

• [Pleural effusion as a first sign of Ig D lambda multiple myeloma].

  Annales de medecine interne 20030201

• Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.

  British journal of cancer 20030127

• High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.

  Cancer 20030101

• Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol.

  European journal of cancer (Oxford, England : 1990) 20030101

• High-dose chemotherapy and autologous peripheral blood stem cell rescue in a patient with pleuropulmonary blastoma.

  Journal of pediatric hematology/oncology 20030101

• Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.

  Internal medicine (Tokyo, Japan) 20030101

• Synthesis and in vivo biodisposition of [14C]-quaternary ammonium-melphalan conjugate, a potential cartilage-targeted alkylating drug.

  Bioconjugate chemistry 20030101

• Relapse in the skull after myeloablative therapy for high-risk neuroblastoma.

  Pediatric hematology and oncology 20030101

• Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma.

  Leukemia & lymphoma 20030101

• [Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].

  Voprosy onkologii 20030101

• High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.

  The National medical journal of India 20030101

• p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer.

  Anticancer research 20030101

• A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma.

  Anticancer research 20030101

• Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma.

  Acta haematologica 20030101

• Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumors.

  Bioconjugate chemistry 20030101

• Breakthroughs in the management of multiple myeloma.

  Drugs 20030101

• Multiple myeloma with amyloidosis presenting with recurrent gastrointestinal bleeding.

  Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20030101

• Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.

  Hepato-gastroenterology 20030101

• Medication sheets for patients. Oral chemotherapy.

  Clinical journal of oncology nursing 20030101

• High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability.

  Tumori 20030101

• Hypoplastic myelodysplastic syndrome transformed in acute myeloid leukemia after androgens and cyclosporin. A treatment.

  Romanian journal of internal medicine = Revue roumaine de medecine interne 20030101

• Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.

  Blood 20021215

• Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

  Blood 20021215

• Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif.

  The Journal of biological chemistry 20021206

• Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.

  Blood 20021201

• Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.

  Bone marrow transplantation 20021201

• Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature.

  Clinical and laboratory haematology 20021201

• Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.

  Bone marrow transplantation 20021201

• A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.

  Bone marrow transplantation 20021201

• High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.

  Bone marrow transplantation 20021201

• High-dose therapy and immunomodulatory drugs in multiple myeloma.

  Seminars in oncology 20021201

• Cytotoxic N-[4-(3-aryl-3-oxo-1-propenyl)phenylcarbonyl]-3,5-bis(phenylmethylene)-4-piperidones and related compounds.

  European journal of medicinal chemistry 20021201

• The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis.

  British journal of cancer 20021118

• Randomized study to evaluate the use of high-dose therapy as part of primary treatment for 'aggressive' lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021115

• Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.

  Blood 20021101

• The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.

  Blood 20021101

• Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

  Blood 20021101

• Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.

  Blood 20021101

• Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia.

  The British journal of ophthalmology 20021101

• Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.

  Bone marrow transplantation 20021101

• Effect of melatonin on the antioxidant enzymes in the kidneys of cyclosporine-treated rats.

  Transplantation proceedings 20021101

• Allergic contact dermatitis from melphalan and chlorambucil: cross-sensitivity or cosensitization?

  Contact dermatitis 20021101

• High dose chemotherapy and allogenic peripheral blood stem cell transplantation for multiple myeloma evolving from intra-abdominal plasmacytoma.

  Zhonghua yi xue za zhi = Chinese medical journal; Free China ed 20021101

• A rare complication of monoclonal gammopathy.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20021001

• Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.

  British journal of haematology 20021001

• Long-term follow-up on a patient with incomplete POEMS syndrome undergoing high-dose therapy and autologous blood stem cell transplantation.

  Blood 20021001

• High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20021001

• Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure.

  Bone marrow transplantation 20021001

• Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?

  Bone marrow transplantation 20021001

• A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients.

  Leukemia & lymphoma 20021001

• Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.

  Leukemia 20020901

• Intensive chemotherapy for children and young adults with metastatic primitive neuroectodermal tumors of the soft tissue.

  Bone marrow transplantation 20020901

• Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.

  Haematologica 20020901

• Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.

  Bone marrow transplantation 20020901

• AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.

  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20020901

• Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.

  Blood 20020801

• Down-regulation of DNA repair in human CD34(+) progenitor cells corresponds to increased drug sensitivity and apoptotic response.

  Blood 20020801

• Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?

  Haematologica 20020801

• Bendamustine in the treatment of multiple myeloma: results and future perspectives.

  Seminars in oncology 20020801

• Isolated limb perfusion in locally advanced cutaneous melanoma.

  Seminars in oncology 20020801

• Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.

  Bone marrow transplantation 20020801

• Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.

  Bone marrow transplantation 20020801

• Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis.

  Bone marrow transplantation 20020801

• Acute myocardial ischemia after high-dose therapy with BEAM regimen.

  Bone marrow transplantation 20020801

• Clinical images: Skeletal muscle pseudo-hypertrophy in myeloma-associated amyloidosis.

  Arthritis and rheumatism 20020801

• Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model.

  Surgery 20020801

• A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2).

  Annals of hematology 20020801

• Leptomeningeal relapse of multiple myeloma following allogeneic stem cell transplantation.

  Leukemia research 20020701

• beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.

  Experimental hematology 20020701

• Unusual implantation site of a port-a-cath system via the right femoral vein.

  Journal of cancer research and clinical oncology 20020701

• Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.

  Annals of hematology 20020701

• [Initial scleromyxedema. Successful treatment with melphalan].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20020701

• [Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20020701

• Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

  Lancet (London, England) 20020615

• Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.

  British journal of haematology 20020601

• Primary systemic amyloidosis.

  Current treatment options in oncology 20020601

• Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

  British journal of haematology 20020601

• Necrobiotic xanthogranuloma with lambda paraproteinemia: case report of successful treatment with melphalan and prednisone.

  The Journal of dermatological treatment 20020601

• [Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].

  Anales de medicina interna (Madrid, Spain : 1984) 20020601

• Autologous stem cell transplantation in patients with mantle cell lymphoma.

  Leukemia & lymphoma 20020601

• Modulation of cytostatic efficacy of melphalan by glutathione: mechanisms and efficacy.

  Chemico-biological interactions 20020520

• Expression of rat liver glutathione-S-transferase GSTA5 in cell lines provides increased resistance to alkylating agents and toxic aldehydes.

  Chemico-biological interactions 20020520

• Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma.

  Journal of medicinal chemistry 20020509

• Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020415

• High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020415

• Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.

  Bone marrow transplantation 20020401

• Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases.

  Bone marrow transplantation 20020401

• Treatment of myeloma: recent developments.

  Anti-cancer drugs 20020401

• Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.

  Internal medicine (Tokyo, Japan) 20020401

• Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.

  Advances in clinical pathology : the official journal of Adriatic Society of Pathology 20020401

• Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.

  Blood 20020315

• Multiple myeloma in association with sarcoidosis.

  Archives of pathology & laboratory medicine 20020301

• Covalent binding of nitrogen mustards to the cysteine-34 residue in human serum albumin.

  Archives of toxicology 20020301

• 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors.

  Cancer 20020301

• Posttransplant adoptive immunotherapy with interleukin-2 in children suffering from neuroectodermal tumors with poor prognosis.

  Transplantation proceedings 20020301

• Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.

  International journal of oncology 20020201

• Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

  Blood 20020201

• Acute leukemia of plasmablastic type as terminal phase of multiple myeloma.

  Haematologica 20020201

• Reversible restrictive cardiomyopathy due to light-chain deposition disease.

  Mayo Clinic proceedings 20020201

• Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.

  Leukemia 20020201

• Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.

  Leukemia 20020201

• [Nonsecretory primary plasma cell leukemia successfully treated with VAD and MP therapy].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20020201

• Influence of phenytoin on the disposition of irinotecan: a case report.

  Journal of pediatric hematology/oncology 20020201

• Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.

  European journal of haematology 20020201

• Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020115

• Autotransplantation for chronic myeloid leukemia: is it useful?

  Haematologica 20020101

• In vitro thermo- and thermochemo-sensitivity of retinoblastoma cells from surgical specimens.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20020101

• Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma.

  American journal of surgery 20020101

• Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma.

  Clinical and experimental rheumatology 20020101

• Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.

  Leukemia & lymphoma 20020101

• The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20020101

• Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.

  Anticancer research 20020101

• Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20020101

• [Peripheral blood hematopoietic cell transplant using immunosuppressive chemotherapy without bone marrow destruction: 'minitransplant'].

  Gaceta medica de Mexico 20020101

• VAD followed by VMCP: an alternative regimen for multiple myeloma.

  Medical oncology (Northwood, London, England) 20020101

• High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.

  Annals of transplantation 20020101

• [High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].

  Voprosy onkologii 20020101

• [Salvage thermochemotherapy in advanced refractory malignant tumors in children].

  Voprosy onkologii 20020101

• Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.

  Cancer treatment and research 20020101

• Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.

  Drugs & aging 20020101

• Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.

  Medical oncology (Northwood, London, England) 20020101

• [Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].

  Voprosy onkologii 20020101

• Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan.

  Journal of proteome research 20020101

• Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation.

  The Journal of biological chemistry 20011214

• Diagnosis and management of multiple myeloma.

  British journal of haematology 20011201

• The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange.

  Carcinogenesis 20011201

• Early clinical diagnosis of solitary plasmacytoma of the jaws: a case report with a six year follow-up.

  International journal of oral and maxillofacial surgery 20011201

• Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.

  Blood 20011115

• Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20011101

• Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression.

  Journal of immunology (Baltimore, Md. : 1950) 20011101

• Treatment with chemotherapy of scleredema associated with Ig A myeloma.

  International journal of dermatology 20011101

• Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.

  Bone marrow transplantation 20011101

• High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.

  Bone marrow transplantation 20011101

• Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.

  Bone marrow transplantation 20011101

• A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.

  Bone marrow transplantation 20011101

• Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.

  Journal of pediatric hematology/oncology 20011101

• Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells.

  Molecular cancer therapeutics 20011101

• In vitro evidence for homologous recombinational repair in resistance to melphalan.

  Journal of the National Cancer Institute 20011003

• FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results.

  Clinical nuclear medicine 20011001

• Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.

  The Journal of rheumatology. Supplement 20011001

• An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

  Bone marrow transplantation 20011001

• Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.

  Bone marrow transplantation 20011001

• Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.

  Bone marrow transplantation 20011001

• Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group.

  The Tohoku journal of experimental medicine 20011001

• Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents.

  Human gene therapy 20010920

• Sensitization to the cytotoxicity of melphalan by ethacrynic acid and hyperthermia in drug-sensitive and multidrug-resistant Chinese hamster ovary cells.

  Radiation research 20010901

• High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.

  Gynecologic oncology 20010901

• Results of autologous stem cell transplant in multiple myeloma patients with renal failure.

  British journal of haematology 20010901

• [Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome].

  Bulletin du cancer 20010901

• Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.

  Bone marrow transplantation 20010901

• Cytotoxicity and effect on collagen biosynthesis of proline analogue of melphalan as a prolidase-convertible prodrug in cultured human skin fibroblasts.

  Farmaco (Societa chimica italiana : 1989) 20010901

• [High dose therapy with autologous stem cell support--finally a progress in myelomatosis].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20010830

• Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.

  Cancer research 20010815

• Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma.

  British journal of cancer 20010801

• Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation.

  Bone marrow transplantation 20010801

• Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.

  Cancer chemotherapy and pharmacology 20010801

• [Treatment of multiple myeloma in elderly patients: consensus of the Geriatric Oncology Working Group of the German Society of Hematologic Oncology and the German Society of Geriatrics].

  Onkologie 20010801

• Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?

  Transplantation 20010727

• Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.

  Neurology 20010710

• Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.

  British journal of cancer 20010701

• Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.

  Seminars in hematology 20010701

• Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM).

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20010701

• Acute left ventricular failure following melphalan and fludarabine conditioning.

  Bone marrow transplantation 20010701

• High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.

  Bone marrow transplantation 20010701

• Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?

  Annals of hematology 20010701

• Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.

  Cancer chemotherapy and pharmacology 20010701

• Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents.

  Bioorganic & medicinal chemistry letters 20010604

• Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells.

  Journal of immunology (Baltimore, Md. : 1950) 20010601

• High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010601

• Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion.

  Canadian journal of surgery. Journal canadien de chirurgie 20010601

• [Treatment of AL amyloidosis].

  La Revue de medecine interne 20010601

• Management of patients with multiple myeloma: emphasizing the role of high-dose therapy.

  Clinical lymphoma 20010601

• [Acquired C1-esterase inhibitor deficiency with angioedema in lymphoplasmocytic lymphoma].

  Praxis 20010523

• Treatment of refractory hand warts by isolated limb infusion with melphalan and actinomycin D.

  The Australasian journal of dermatology 20010501

• Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

  Annals of internal medicine 20010501

• Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness.

  European journal of cancer (Oxford, England : 1990) 20010501

• Bizarre epithelial atypia of the sinonasal tract after chemotherapy.

  The American journal of surgical pathology 20010501

• Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010501

• Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis.

  Transplantation proceedings 20010501

• Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.

  European journal of haematology 20010501

• High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.

  Bone marrow transplantation 20010501

• High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results.

  Bone marrow transplantation 20010501

• Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

  Journal of pediatric hematology/oncology 20010501

• Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.

  Journal of pediatric hematology/oncology 20010501

• Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010401

• Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.

  British journal of haematology 20010401

• Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010401

• Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats.

  Human gene therapy 20010320

• Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity.

  The Journal of biological chemistry 20010316

• The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.

  British journal of haematology 20010301

• Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.

  Journal of medicinal chemistry 20010301

• Latent hematopoietic stem cell toxicity associated with protracted drug administration.

  Experimental hematology 20010301

• Characterization of DNA fragmentation events caused by genotoxic and non-genotoxic agents.

  Mutation research 20010220

• A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.

  Journal of medicinal chemistry 20010215

• How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010201

• Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

  Blood 20010201

• Fatal upper and lower gastrointestinal cytomegalovirus disease following autologous peripheral blood stem cell transplantation.

  European journal of haematology 20010201

• Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.

  Surgery 20010201

• A bioreversible prodrug approach designed to shift mechanism of brain uptake for amino-acid-containing anticancer agents.

  Journal of neurochemistry 20010201

• High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity.

  Leukemia 20010201

• A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.

  Bone marrow transplantation 20010201

• Multiple myeloma in elderly patients: presenting features and outcome.

  European journal of haematology 20010101

• Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.

  European journal of haematology 20010101

• Antibody recognition of melphalan adducts characterized using immobilized DNA: enhanced alkylation of G-Rich regions in cells compared to in vitro.

  Chemical research in toxicology 20010101

• The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.

  Cancer chemotherapy and pharmacology 20010101

• High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).

  Annals of oncology : official journal of the European Society for Medical Oncology 20010101

• Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes.

  Bone marrow transplantation 20010101

• Conjugation with L-Glutamate for in vivo brain drug delivery.

  Journal of drug targeting 20010101

• Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups.

  The hematology journal : the official journal of the European Haematology Association 20010101

• Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.

  American journal of hematology 20010101

• [Intracytoplasmic crystals and Fanconi syndrome in a patient with IgA kappa myeloma].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101

• Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.

  Medical and pediatric oncology 20010101

• [A patient with Crow-Fukase syndrome associated with pulmonary plasmacytoma].

  Rinsho shinkeigaku = Clinical neurology 20010101

• Pharmaco-economic study of intensive chemotherapy with peripheral blood progenitor cell support for advanced breast cancer.

  Oncology reports 20010101

• Proline analogue of melphalan as a prolidase-convertible pro-drug in breast cancer MCF-7 cells.

  Folia histochemica et cytobiologica 20010101

• Communication challenges in a young man with Hodgkin's disease.

  Cancer practice 20010101

• Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.

  The hematology journal : the official journal of the European Haematology Association 20010101

• In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.

  Cytotherapy 20010101

• Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.

  Cytotherapy 20010101

• [High dose chemotherapy and hematopoietic stem cell transplantation in patients with myeloma].

  Polskie Archiwum Medycyny Wewnetrznej 20010101

• [Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies].

  Polskie Archiwum Medycyny Wewnetrznej 20010101

• Myeloblastoma (chloroma) in leukemia: case 2. Meningeal granulocytic sarcoma (chloroma) in essential thrombocythemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20001201

• Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

  American journal of clinical oncology 20000801

• Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study.

  British journal of haematology 20000801

• Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and cytosine arabinoside in murine fibroblasts.

  Cancer gene therapy 20000501

• The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.

  Bone marrow transplantation 20000301

• A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20000101

• Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment.

  Medical oncology (Northwood, London, England) 19991201

• Encephalopathy complicating high-dose melphalan.

  Bone marrow transplantation 19991101

• Deletion 5q31 in patients with stable, melphalan-treated multiple myeloma.

  Cancer genetics and cytogenetics 19990801

• Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.

  Annals of surgical oncology 19990601

• Genomic cloning and characterization of the rat glutathione S-transferase-A3-subunit gene.

  The Biochemical journal 19990501

• Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma.

  Bone marrow transplantation 19990501

• Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 19990101

• Reticulate scleroderma after isolated limb perfusion with melphalan.

  Journal of the American Academy of Dermatology 19981201

• Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19980701

• Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells.

  Bone marrow transplantation 19980501

• Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.

  Japanese journal of clinical oncology 19980201

• Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 19980101

• Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patients.

  Leukemia 19971201

• High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.

  Bone marrow transplantation 19971101

• A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.

  Bone marrow transplantation 19971101

• Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature.

  Bone marrow transplantation 19971101

• [Assessment of regional and systemic toxicity of isolated hyperthermic extremity perfusion with tumor necrosis factor-alpha and melphalan].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 19970901

• Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.

  In vivo (Athens, Greece) 19970101

• Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours.

  Bone marrow transplantation 19961201

• Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.

  British journal of haematology 19960801

• Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  American journal of hematology 19960501

• Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells.

  Human gene therapy 19960501

• Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study.

  International journal of cancer 19950927

• G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM).

  Experimental hematology 19950401

• Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.

  Archives of surgery (Chicago, Ill. : 1960) 19950101

• Visual hallucinations following treatment with vincristine.

  Clinical and laboratory haematology 19941201

• Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma.

  International journal of hematology 19941201

• Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 19941201

• Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats.

  Cancer research 19940901

• Re: Toxicity of intrathecal melphalan.

  Journal of the National Cancer Institute 19940601

• Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.

  British journal of cancer 19931001

• Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

  Cancer research 19930615

• Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).

  European journal of cancer (Oxford, England : 1990) 19920101

• SWOG 8825: melphalan GM-CSF: a phase I study.

  Gynecologic oncology 19920101

• High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma.

  Bone marrow transplantation 19911201

• Interaction of melphalan and dexamethasone in a human myeloma cell line.

  Anti-cancer drugs 19911201

• Cyclophosphamide-associated carcinoma of urothelium: modalities for prevention.

  Urology 19911101

• Multiple myeloma with coexistent myelofibrosis: improvement of myelofibrosis following recovery from multiple myeloma after treatment with melphalan and prednisolone.

  Japanese journal of medicine 19910101

• Synthesis of alpha-MSH fragments containing phenylalanine mustard for receptor studies.

  International journal of peptide and protein research 19900901

• Cytogenetic abnormalities in acute leukemia complicating melphalan-treated multiple myeloma.

  Cancer genetics and cytogenetics 19900801

• Determinants of drug response in a cisplatin-resistant human lung cancer cell line.

  Japanese journal of cancer research : Gann 19900501

• [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].

  Sangre 19900401

• Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine.

  Journal of medicinal chemistry 19900201

• [Hepatic veno-occlusive disease in a patient undergoing bone marrow autotransplant after busulfan and melphalan conditioning].

  Medicina clinica 19900127

• [Enhancing factors in the cardiotoxicity of anthracyclines].

  Anales espanoles de pediatria 19900101

• Synthesis of 5-[1-hydroxy(or methoxy)-2-bromo(or chloro)ethyl]-2'-deoxyuridines and related halohydrin analogues with antiviral and cytotoxic activity.

  Journal of medicinal chemistry 19890501

• Prednisone mood disorder with associated catatonia.

  Journal of geriatric psychiatry and neurology 19890101

• [A case report of acute renal failure induced by melphalan in a patient with ovarian cancer].

  Gan no rinsho. Japan journal of cancer clinics 19881101

• Successful treatment of peripheral neuropathy with chemotherapy in osteosclerotic myeloma.

  Journal of neurology 19870501

• Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.

  Investigational new drugs 19870101

• L-phenylalanine mustard-dianhydrogalactitol and hyponatremia.

  Pediatric hematology and oncology 19860101

• Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

  Cancer chemotherapy and pharmacology 19860101

• Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.

  Cancer chemotherapy and pharmacology 19850101

• Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan.

  Cancer 19850101

• Drug testing using a soft agar stem cell assay on patient and xenograft tumor material.

  International journal of radiation oncology, biology, physics 19840901

• A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.

  Gynecologic oncology 19830401

• [Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)].

  Wiener medizinische Wochenschrift (1946) 19820515

• Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.

  Cancer treatment reports 19820301

• Sudden cardiac death following adriamycin therapy.

  Cancer 19810701

• Vindesine therapy in melphalan-resistant multiple myeloma.

  European journal of cancer 19810201

• Lymphocyte transformation studies in drug hypersensitivity.

  Canadian Medical Association journal 19790505

• Vasculitis and melphalan.

  JAMA 19781215

• Cytomegalovirus pneumonia after treatment with melphalan and prednisone. Report of a case.

  Acta medica Scandinavica 19780101

• [Refractory anemia with partial myeloblastosis in multiple myeloma treated with melphalan].

  La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris 19770401

• Carcinoma of the breast. Occurence after treatment with melphalan for multiple myeloma.

  JAMA 19761004

• [Diagnosis and treatment of plasma cell leukemia].

  Deutsche medizinische Wochenschrift (1946) 19730427

• Prolonged apnea after succinylcholine in a case treated with cytostatics for cancer.

  Anesthesia and analgesia 19720101